Netto winst iets afgenomen.
En zoals verwacht een SLAPPE outlook! Is dit alles?!
Outlook
For the remainder of 2021, the Company expects:
• Continued growth in revenues from sales of RUCONEST®, mainly driven by the US and expanded EU operations, subject to the progression of the COVID-19 pandemic, with quarterly fluctuations in revenues expected, as a result of the ongoing effects of the pandemic on access to customers and phasing of ordering patterns.
• Maintenance of positive net earnings during the year, we therefore do not expect to require additional financing to maintain the current business.
• Investments in acquisitions and in-licensing of new development opportunities and assets, as these occur.
• Continued investment in the expansion of production of RUCONEST® and production of leniolisib
• Investment in pre-marketing activities for leniolisib and the continuing registration- enabling study for leniolisib for APDS, as well as our ongoing clinical trials for rhC1INH and other development activities.
• Continued close monitoring of the ongoing COVID-19 pandemic and the potential impact on the business.
No further specific financial guidance for 2021 is provided.